<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00792753</url>
  </required_header>
  <id_info>
    <org_study_id>ELX-CL-0801</org_study_id>
    <nct_id>NCT00792753</nct_id>
  </id_info>
  <brief_title>Elixir Medical Clinical Evaluation of the Novolimus-Eluting Coronary Stent System: A Randomized Study &quot;EXCELLA II STUDY&quot;</brief_title>
  <official_title>A Randomized, Single Blind, Consecutive Enrollment Evaluation of the Elixir Novolimus-Eluting Coronary Stent System With Durable Polymer Compared to the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment Of Patients With De Novo Native Coronary Artery Lesions And A Randomized, Consecutive Enrollment Evaluation of the Elixir Novolimus-Eluting Coronary Stent System With Bioabsorbable Polymer Compared to the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment Of Patients With De Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elixir Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elixir Medical Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized Study To evaluate the safety and effectiveness of the Elixir Medical DESyne
      Novolimus-Eluting Coronary Stent System with Durable Polymer through the assessment of
      clinical, angiographic and IVUS endpoints as compared to the concurrently enrolled Medtronic
      Zotarolimus-Eluting Coronary Stent System in a randomized, single blind study of up to 200
      male and female patients. In a Continued Access Registry of up to 100 patients receiving the
      DESyne Stent clinical-only endpoints will be evaluated.

      To evaluate the safety and effectiveness of the Elixir Novolimus-Eluting Coronary Stent
      System with bioabsorbable polymer as compared to the Medtronic Endeavor Zotarolimus-Eluting
      Coronary Stent System control through clinical and angiographic endpoints.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 8, 2014</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent late lumen loss assessed by QCA</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device-oriented Composite Endpoints</measure>
    <time_frame>1, 6, 9, and 12 months and annually to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1. DESyne DES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test arm: Intervention with DESyne Novolimus-Eluting Coronary Stent DESyne Novolimus Stent System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Medtronic Endeavor DES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control arm: Intervention with Medtronic Endeavor Zotarolimus-Eluting Coronary Stent Medtronic Endeavor Coronary Stent System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3. DESyne BD DES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test arm: Intervention with DESyne BD Novolimus-Eluting Coronary Stent DESyne BD Novolimus Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic Endeavor Coronary Stent System</intervention_name>
    <description>coronary stent implantation</description>
    <arm_group_label>2. Medtronic Endeavor DES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DESyne BD Novolimus Stent System</intervention_name>
    <description>coronary stent implantation</description>
    <arm_group_label>3. DESyne BD DES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DESyne Novolimus Stent System</intervention_name>
    <description>coronary stent implantation</description>
    <arm_group_label>1. DESyne DES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has a planned intervention of a single lesion in one or two separate major
             epicardial territories. Each lesion/vessel must meet the following criteria:

          -  De novo

          -  The target lesion reference site must be visually estimated to be &gt; 2.5 mm and &lt; 3.5
             mm in diameter.

          -  The target vessel must be a major coronary artery or major branch with a visually
             estimated stenosis of &gt; 50% and &lt;100%.

          -  The visually estimated target lesion must be able to be covered by a single, 14, 18 or
             28mm stent Elixir Stent or a single 14, 18, 24 or 30mm Endeavor Stent. Note that the
             8mm Endeavor Stent will not be used in this study.

          -  Maximum lesion length is 24 mm.

          -  &gt; TIMI 1 coronary flow.

        Exclusion Criteria:

          -  The patient has a known hypersensitivity or contraindication to aspirin, heparin,
             ticlopidine, clopidogrel, mTOR inhibitor class drugs, cobalt chromium alloy,
             methacrylate or polylactide polymer, or sensitivity to contrast which cannot be
             adequately premedicated.

          -  There will be an untreated significant lesion of &gt; 40% diameter stenosis remaining
             proximal or distal to the target site after the planned intervention.

          -  Total occlusion or TIMI 0 coronary flow in the target vessel.

          -  Restenosis lesion

          -  The proximal target vessel or target lesion is severely calcified by visual
             assessment.

          -  Aorto-ostial location, unprotected left main lesion location, or a lesion within 5 mm
             of the origin of the LAD or LCX.

          -  Lesion involvement of a significant side branch (branch diameter &gt; 2 mm) that would be
             covered by stenting.

          -  The patient has suffered a myocardial infarction with total creatine kinase (CK) &gt;2
             times normal within the past 72 hours (exactly three days).

          -  The patient has a history of bleeding diathesis or coagulopathy or will refuse blood
             transfusions.

          -  The patient suffered a stroke, transient ischemic neurological attack (TIA) or
             significant gastrointestinal (GI) bleed within the past six months.

          -  The patient has renal insufficiency as determined by a creatinine of &gt; 2.0mg/dl.

          -  The target lesion, or the target vessel proximal to the target lesion, contains
             thrombus.

          -  Documented left ventricular ejection fraction of &lt; 25%.

          -  The patient is a recipient of a heart transplant.

          -  The patient has extensive peripheral vascular disease that precludes safe 6 French
             sheath insertion or extreme anti-coagulation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick W Serruys, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thoraxcentrum, Rotterdam, Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Monash Medical Center</name>
      <address>
        <city>Melbourne</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese</name>
      <address>
        <city>Sao Paulo</city>
        <zip>0401210</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herz- und Gefäßzentrum</name>
      <address>
        <city>Hamburg</city>
        <zip>22527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxcentrum</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jagiellonian University</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Iqbal J, Verheye S, Abizaid A, Ormiston J, de Vries T, Morrison L, Toyloy S, Fitzgerald P, Windecker S, Serruys PW. DESyne novolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial. EuroIntervention. 2016 Dec 10;12(11):e1336-e1342. doi: 10.4244/EIJY15M10_04.</citation>
    <PMID>26465374</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2008</study_first_submitted>
  <study_first_submitted_qc>November 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2008</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

